{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":2,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":29,"n_cols":5,"rows_kept":29,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[11,2,11,3],[11,4,11,5],[12,2,12,3],[12,4,12,5],[13,2,13,3],[13,4,13,5],[14,2,14,3],[15,2,15,3],[17,2,17,3],[18,2,18,3],[19,2,19,3],[21,2,21,3],[22,2,22,3],[23,2,23,3],[27,2,27,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910571712003321"]
[null,null,"Autore",null,"LUCARELLI SONIA"]
[null,null,"Titolo",null,"Gender and the European Union"]
[null,null,"Pubbl/distr/stampa",null,"Florence, : Firenze University Press, 2014"]
[null,null,"Descrizione fisica",null,"1 electronic resource (78 p.)"]
[null,null,"Collana",null,"Strumenti per la didattica e la ricerca"]
[null,null,"Soggetti",null,"Political science & theory"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Sommario/riassunto","Gender discrimination continues to be a reality in several parts of the world, also in Europe. The aim of this book is to provide an overview of both European Union’s (EU) gender policies and gender balance in EU institutions. It does so by looking at gender equality policies and the EU legal system concerning gender equality, women’s representation within diff erent institutions (and more particularly in the European External Action Service), gender rights as a type of human rights and the EU’s role in the external promotion of womens’ rights in third countries. The analysis shows that women’s representation in the EU institutions has increased in the last decades and that the EU has strengthened its att ention to gender rights in its external relations as well, however the results of both att empts are far from being fully satisfactory."]
[null,"2.","Record Nr.",null,"UNINA9910969216603321"]
[null,null,"Autore",null,"Podar Klaus"]
[null,null,"Titolo",null,"Multiple myeloma : a new era of treatment strategies / / editors, Klaus Podar, Kenneth C. Anderson"]
[null,null,"Pubbl/distr/stampa",null,"[U.S.A.], : Bentham Science Publishers, [2012]"]
[null,null,"ISBN",null,"9781608052974"]
[{"$nulls":4},"1608052974"]
[null,null,"Edizione",null,"[1st ed.]"]
[null,null,"Descrizione fisica",null,"1 online resource (217 p.)"]
[null,null,"Disciplina",null,"616.99/418"]
[{"$nulls":4},"616.99418"]
[null,null,"Soggetti",null,"Multiple myeloma - Treatment"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"section 1. Multiple myeloma -- section 2. Treatment guidelines -- section 3. The bone marrow microenvironment and the pathogenesis of multiple myeloma -- section 4. New treatment strategies."]
[null,null,null,"Sommario/riassunto","Multiple Myeloma (MM), the second most common blood cancer in adults, is a clonal plasma cell malignancy within the bone marrow characterized by osteolytic bone lesions, renal disease, and immunodeficiency. It is now well established that MM cell- induced disruption of the bone marrow homeostasis between the highly organized cellular and extracellular compartments supports MM cell proliferation, survival, migration, and drug resistance via activation of various signaling pathways. Based on this knowledge, the prototypic drugs thalidomide, bortezomib, and lenalidomide, which target both MM cell"]